Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 16/20 | 0.74 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.74 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7620175 | 0.90 | PTPN1 (0.59) | PTPN1PTPN2EPHX2PPARGCHRM1 | |
| SCHEMBL7165170 | 0.86 | PTPN1 (0.74) | PTPN1PTPN2EPHX2PPARGLMNA | |
| SCHEMBL7161699 | 0.85 | PTPN1 (1.00) | PTPN1PTPN2 | |
| SCHEMBL21067870 | 0.85 | PTPN1 (1.00) | PTPN1PTPN2 | |
| SCHEMBL7625002 | 0.85 | PTPN1 (0.67) | PTPN1PTPN2EPHX2PPARGCHRM1 | |
| SCHEMBL7626425 | 0.85 | PTPN1 (0.54) | PTPN1PTPN2EPHX2PPARG | |
| SCHEMBL7623925 | 0.84 | PTPN1 (0.68) | PTPN1PTPN2EPHX2PPARGCHRM1 | |
| SCHEMBL7622074 | 0.83 | PTPN1 (0.71) | PTPN1PTPN2EPHX2PPARGLMNA | |
| SCHEMBL7618267 | 0.83 | PTPN1 (0.51) | PTPN1PTPN2 | |
| SCHEMBL7621370 | 0.82 | PTPN1 (0.65) | PTPN1PTPN2EPHX2PPARGCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777433-B2 | BIS((DIFLUORO-PHOSPHONATO-METHYL)PHENYL) DERIVATIVES; ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2004-08-17 | — | — | US | disclosed |
| US-20030114703-A1 | Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates | MERCK FROSST CANADA LTD. (CA) | 2003-06-19 | — | — | US | disclosed |
| US-6448429-B1 | TREATING OR PREVENTING PTP-1B MEDIATED DISEASES, INCLUDING DIABETES, OBESITY, AND DIABETES-RELATED CONDITIONS. | MERCK FROSST CANADA & CO. (CA) | 2002-09-10 | — | — | US | disclosed |
| US-20020052347-A1 | Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates | MERCK FROSST CANADA LTD. (CA) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114703-A1 | Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates | PTPRO, PTPN1, PTPRS | PTPN1 2/4885PTPN2 22/4885EPHX2 2249/4885 |
| US-20020052347-A1 | Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates | PTPRO, PTPN1, PTPRS | PTPN1 2/4885PTPN2 22/4885EPHX2 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.